MIT chemical engineers unveiled an automated, self-correcting platform that rapidly produces lipid nanoparticles with precisely controlled sizes and shapes. The system aims to accelerate RNA therapy development, including RNA vaccine design, by reducing trial-and-error formulation iteration and enabling faster optimization loops.